Cargando…
An update on immunotherapy with PD-1 and PD-L1 blockade
Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer. Since then, drugs with mechanisms related to tumor immunity, especially immune checkpoint inhibitors, have proven effective, and...
Autor principal: | Koh, Sung Ae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yeungnam University College of Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688791/ https://www.ncbi.nlm.nih.gov/pubmed/34496466 http://dx.doi.org/10.12701/yujm.2021.01312 |
Ejemplares similares
-
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015) -
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020) -
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019) -
Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022) -
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)